London, UK – 23 November 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has been granted its fifth patent by the US Patent and Trademark Office (USPTO). This is COMPASS’s 10 th patent overall, with five now granted in the US, two in the UK…


Previous articleNuminus to Host Q4 and 2021 Annual Results Conference Call on December 9, 2021
Next articlePT274 – Juan Pablo Cappello – Nue Life: Using Digital Phenotyping to Personalize Healthcare